Despite the significant achievements in the diagnosis and treatment of metastatic breast
cancer (MBC), this condition remains substantially an incurable disease. In recent years …

Purpose: PIK3CA mutations are frequent in breast cancer and activate the PI3K/Akt pathway.
Unexpectedly, PIK3CA mutation appears in general to be associated with better outcome. In …

PIK3CA mutation frequency varies among breast cancer (BC) subtypes. Recent evidence
suggests combination therapy with the PI3K inhibitor (PI3Ki) alpelisib and endocrine therapy …

Background α-Selective phosphatidylinositol 3-kinase (PI3K) inhibitors improve outcome in
patients with PIK3CA-mutated, hormone receptor-positive (HR+)/Her2− metastatic breast …

Abstract Background Phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit
alpha, PIK3CA, is one of the most frequently mutated genes in breast cancer, and the …

Introduction PIK3CA is the oncogene showing the highest frequency of gain-of-function
mutations in breast cancer, but the prognostic value of PIK3CA mutation status is …

Deregulation of the phosphoinositide 3-kinase (PI3K) pathway contributes to the
development and progression of tumors. Here, we determine that somatic mutations in …

Abstract Purpose The therascreen PIK3CA mutation assay and the alpha-specific PI3K
inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced …

The PI3K pathway is the most frequently enhanced oncogenic pathway in breast cancer.
Among mechanisms of PI3K enhancement, PIK3CA mutations are most frequently (∼ 30%) …

Abstract The phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit alpha
(PIK3CA) gene is frequently mutated in breast cancer (BCa). Sex hormone receptors (HRs) …